Across 100 patients in three Phase III studies, Vertex's Casgevy showed lasting benefits for more than five years.

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

The endometriosis market is expected to grow from $938.0m in 2024 to $2.5 billion in 2034, at a compound annual growth rate ...

Tango has dosed the first subject in the Phase I/II trial of TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib.

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

BioAtla has presented first-in-human Phase I study data of its anticancer therapy, BA3182, targeting those with metastatic adenocarcinoma.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Cidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational ...

Neuron23 has dosed the first subject in the global Phase II NEULARK trial of NEU-411 for early Parkinson's disease (PD).